GO
Loading...

GlaxoSmithKline PLC

More

  • *Investors focused on possible Pfizer return. LONDON, July 31- AstraZeneca raised its sales and earnings forecasts for the year on Thursday, showing resilience after seeing off a $118 billion takeover approach from rival Pfizer two months ago.

  • LONDON, July 31- AstraZeneca smashed forecasts for second-quarter sales and earnings on Thursday, demonstrating resilience after seeing off a $118 billion takeover approach from rival drugmaker Pfizer two months ago.

  • *FDA lists 10 violations at Taiwan plant. July 29- Impax Laboratories Inc said the U.S. Food and Drug Administration raised concerns about the company's factory in Taiwan, casting in doubt the future of its Parkinson's drug, rytary.

  • China to put Glaxo investigators on trial Aug. 8 Tuesday, 29 Jul 2014 | 4:24 AM ET

    BEIJING— A Shanghai court says American and British investigators who worked for drug maker GlaxoSmithKline will stand trial Aug. 8 on charges of illegally obtaining information on Chinese citizens. 1 Intermediate People's Court said Tuesday that Yingzeng Yu and her husband Peter Humphrey will have a "public trial."

  • Europe backs new leukemia drugs from J&J and Gilead Friday, 25 Jul 2014 | 7:20 AM ET

    LONDON, July 25- Two new leukemia drugs from Johnson& Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months. The European Medicines Agency said on Friday its experts had issued positive opinions for J&J's ibrutinib, developed with Pharmacyclics, and Gilead's idelalisib.

  • EXCLUSIVE-Allegations of GSK corruption spread to Syria Thursday, 24 Jul 2014 | 1:19 PM ET

    LONDON, July 24- GlaxoSmithKline faces new allegations of corruption, this time in Syria, where the drugmaker and its distributor have been accused of paying bribes to secure business, according to a whistleblower's email reviewed by Reuters.

  • LONDON, July 24- GlaxoSmithKline said on Thursday it is applying for regulatory approval for the world's first vaccine against malaria, designed for use in children in Africa.

  • GSK seeks approval for world's first malaria vaccine Thursday, 24 Jul 2014 | 6:00 AM ET

    LONDON, July 24- GlaxoSmithKline is applying for regulatory approval for the world's first vaccine against malaria, designed for use in children in Africa.

  • Delta and Apple are big market movers Wednesday, 23 Jul 2014 | 4:38 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:. Delta Air Lines Inc., up $1.47 to $39.15. GlaxoSmithKline Plc., down $3.18 to $50.04.

  • FDA approves Gilead Sciences drug for 3 cancers Wednesday, 23 Jul 2014 | 12:57 PM ET

    WASHINGTON— The Food and Drug Administration on Wednesday approved a new cancer drug from Gilead Sciences Inc. to treat three types of blood cancer. The FDA has approved three other drugs for the disease in the last year: Roche's Gazyva, Janssen Pharmaceutical's Imbruvica and GlaxoSmithKline's Arzerra.

  • LONDON, July 23- Britain's fraud office is working with authorities in China in a first for such Anglo-Chinese cooperation as it carries out its own investigation into alleged corruption at drugmaker GlaxoSmithKline.

  • Europe closes higher despite Ukraine tensions Wednesday, 23 Jul 2014 | 11:31 AM ET

    European shares closed higher on Wednesday amid corporate earnings news and ongoing turmoil in Gaza and Ukraine.

  • LONDON, July 23- GlaxoSmithKline cut its 2014 earnings outlook after sales fell by a worse-than-expected 13 percent in the second quarter as its all-important lung drugs struggled in the United States and a strong pound took a bite out of growth.

  • Cramer: This stock could quadruple Wednesday, 23 Jul 2014 | 10:57 AM ET
    Jim Cramer

    Results of a clinical trial of a breast cancer drug could make this company a takeover target, too, says CNBC's Jim Cramer.

  • GSK cuts earnings forecast after weak 2nd quarter Wednesday, 23 Jul 2014 | 9:28 AM ET

    LONDON— Drug maker GlaxoSmithKline has cut its full-year earnings expectations as it says its second-quarter profits were hit by currency moves and a fall in sales of its respiratory drugs. The company said Wednesday it expects 2014 earnings per share to be broadly similar to last year.

  • UPDATE 2-GSK warns on profits as weak lung drug sales hit Wednesday, 23 Jul 2014 | 9:12 AM ET

    LONDON, July 23- GlaxoSmithKline cut its 2014 earnings outlook after sales fell by a worse-than-expected 13 percent in the second quarter as its all-important lung drugs struggled in the United States and a strong pound took a bite out of growth.

  • LONDON, July 23- GlaxoSmithKline cut its 2014 outlook after sales fell by a worse-than-expected 13 percent in the second quarter as its all-important lung drugs struggled in the United States and a strong pound took a bite out of growth.

  • Weak lung drug sales and strong pound hit GlaxoSmithKline Wednesday, 23 Jul 2014 | 7:11 AM ET

    LONDON, July 23- GlaxoSmithKline's sales fell by a worse-than-expected 13 percent in the second quarter as its all-important lung drugs struggled in the United States and a strong pound took a bite out of growth.

  • GSK CEO: 'Very committed' to China despite probe Wednesday, 23 Jul 2014 | 6:59 AM ET

    GlaxoSmithKline's share price plunged immediately following the announcement of its second quarter results on Tuesday.

  • LONDON, July 22- European shares bounced back on Tuesday on some strong earnings reports and after signs of cooperation between Russia and other nations in investigating the shooting down of a Malaysian airliner over Ukraine.